Sonoma Pharmaceuticals (SNOA) to Release Quarterly Earnings on Thursday

Sonoma Pharmaceuticals (NASDAQ:SNOA) will likely be announcing its earnings results before the market opens on Thursday, February 13th. Analysts expect the company to announce earnings of ($0.80) per share and revenue of $4.39 million for the quarter.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last issued its earnings results on Wednesday, February 5th. The company reported ($0.59) earnings per share (EPS) for the quarter. Sonoma Pharmaceuticals had a negative return on equity of 68.98% and a negative net margin of 26.82%. On average, analysts expect Sonoma Pharmaceuticals to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Sonoma Pharmaceuticals Price Performance

Sonoma Pharmaceuticals stock opened at $2.58 on Wednesday. The stock’s 50 day moving average price is $2.68 and its 200 day moving average price is $2.44. Sonoma Pharmaceuticals has a 1-year low of $2.44 and a 1-year high of $9.37. The company has a market cap of $4.18 million, a PE ratio of -0.64 and a beta of 1.43.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.